You are here
- Home
Investor relations
Creating value for shareholders by making the most meaningful difference to patient health through great medicines
-
Latest news collapse
-
02 September 2010
European Commission Issues Positive Decision for Approval of Seroquel XR as an Add-On Treatment of Major Depressive Disorder
AstraZeneca today announced that the European Commission (EC) has issued a positive decision for the approval of once-daily SEROQUEL XR (quetiapine fumarate) Extended Release Tablets as an add-on treatment of major depressive episodes in patients with Major Depressive Disorder (MDD) who have had sub-optimal response to antidepressant monotherapy.
Annual Information Update
Currency Guidance 2010 collapse
Research & Development expand
-
02 September 2010
European Commission Issues Positive Decision for Approval of Seroquel XR as an Add-On Treatment of Major Depressive Disorder
-
Historical sales information
Annual Report 2009 collapse
Latest presentation collapse
Financial results collapse
Second quarter and half year results 2010 announced Thursday, 29 July 2010.
Not signed in
Page tools
Share price
- London
-
33.22 GBP - New York
-
51.26 USD - Stockholm
-
376.10 SEK
At 09-Sep-2010 08:15 GMT
Detailed share priceStock symbol - AZN
Stock symbol - AZN
On LSE, NYSE and OMX

Interactive stock charts
Share holding calculator
Share price look-up
Share price history